ACCESSWIRE

4245 articles with ACCESSWIRE

• Proxima Clinical Research Launches Early Phase Oncology Network for New Investigational Therapies

  3/21/2023

  Proxima Clinical Research ("Proxima CRO") announced today it is expanding its early phase oncology clinical trials offering with its Early Phase Oncology Network, a group of oncology-specific scientific experts and early phase clinical trials clinics that allows for quick and easy site enrollment and expert insight, feedback, and guidance in first-in-human Phase I and Phase II clinical oncology trials.

• Jaguar Health to Hold Investor Webcast Monday, March 27th at 8:30 AM EDT Regarding Q4 2022 Financials & Corporate Updates

  3/21/2023

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, March 27, 2023 at 8:30 a.m. Eastern Daylight Time to review fourth-quarter 2022 financials and provide corporate updates.

• Integrated BioPharma Announces the Sudden Death of Its Executive Chairman and President

  3/21/2023

  Integrated BioPharma, Inc. announced that Edward G. Kay, the Company's Founder, Executive Chairman and President passed away yesterday evening.

• Evotec SE to Announce Preliminary Financial Results for Fiscal Year 2022 on 28 March 2023

  3/21/2023

  Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN: DE0005664809)(NASDAQ:EVO) will announce its preliminary financial results for 2022 on Tuesday, 28 March 2023.

• Diabeloop Announces Collaboration With Novo Nordisk to Pursue Its Interoperability Strategy With Connected Insulin Pens

  3/21/2023

  Diabeloop, a pioneer in Automated Insulin Delivery, will collaborate with leading global healthcare company, Novo Nordisk.

• Mangoceuticals, Inc. Announces Pricing of Initial Public Offering

  3/21/2023

  Mangoceuticals, Inc. ("MangoRx" or the "Company") today announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share for a total of $5,000,000 of gross proceeds to the Company, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

• Halberd Eradicates All Strains of Antibiotic Resistant E. Coli Provided by the CDC at Youngstown State University

  3/21/2023

  Halberd Corporation, leading up to the scheduled meeting with the Centers for Disease Control on March 29, 2023, is pleased to report it has successfully eradicated all of the strains of antibiotic resistant E.

• Dermata Therapeutics Announces Closing of $5.0 Million Public Offering

  3/20/2023

  Dermata Therapeutics, Inc. announced the closing of its previously announced public offering of 1,618,123 shares of the Company's common stock and accompanying Series A warrants to purchase up to 1,618,123 shares of common stock and Series B warrants to purchase up to 1,618,123 shares of common stock at a combined offering price of $3.09 per share of common stock and accompanying warrants.

• Plandai Biotechnology, Inc. Announces Entry into Material Share Exchange Agreement with Good Salt, LLC

  3/20/2023

  Plandai Biotechnology, Inc. (OTC PINK:PLPL) announces it has entered into a binding memorandum of understanding to close a share exchange agreement with Good Salt, LLC, a Florida limited liability company.

• GB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in China

  3/20/2023

  Gb Sciences, Inc. has recently been issued a patent in China to protect its proprietary cannabinoid-containing formulation for the treatment of Parkinson's disease.

• First Patient Dosed in Europe in Clairvoyant’s Phase 2b Clinical Trial Exploring Psilocybin Therapy as a Treatment for Alcohol Use Disorder

  3/20/2023

  Clairvoyant Therapeutics is pleased to announce that the first clinical trial participant in Finland enrolled in CLA-PSY-201 has received their first dose of the drug along with Motivational Enhancement Therapy (MET). CLA-PSY-201 is the company's placebo-controlled, randomized, multi-site phase 2b trial exploring psilocybin therapy as a treatment for alcohol use disorder (AUD).

• Biofrontera Inc. to Attend 2023 American Academy of Dermatology Annual Meeting

  3/17/2023

  Biofrontera Inc. announced that it will be hosting a booth showcasing its innovative, FDA-approved products at the 2023 American Academy of Dermatology Annual Meeting taking place March 17-21, 2023 in New Orleans, LA.

• Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting

  3/17/2023

  RELIEF THERAPEUTICS Holding SA announced the Company will present the results of pre-clinical research evaluating the metabolic impact of PKU GOLIKE® on nitrogen balance, muscle strength and glucose.

• Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2023

  3/17/2023

  Pharma-Bio Serv, Inc. announced that revenues for the quarter ended January 31, 2023 were approximately $4.2 million, a net decrease of approximately $0.8 million when compared to the same period last year.

• IRLAB to Hold Four Presentations at Scientific Congress AD/PD(TM) 2023

  3/17/2023

  IRLAB Therapeutics AB announced that it will present new data in an oral presentation and hold three poster presentations at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, AD/PD ™ 2023, held on March 28- April 1, 2023, in Gothenburg, Sweden.

• Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe

  3/16/2023

  RELIEF THERAPEUTICS Holding SA is pleased to announce the availability of the newest PKU GOLIKE BARs ® in Europe.

• Q3 Interim Report November -January 2022/2023

  3/16/2023

  Biovica International DiviTum® TKa ready for clinical use in the US

• Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event

  3/16/2023

  Xenetic Biosciences, Inc. today announced that it will participate in the Virtual Investor NETs in Cancer Spotlight Event on Wednesday, March 29, 2023 at 11:00 AM ET.

• Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb

  3/16/2023

  Evotec SE announced progress within the Company's strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.

• NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease Test

  3/16/2023

  NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today the commercial availability of the RaDaR assay, a liquid biopsy test for molecular/minimal residual disease (MRD).